Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Study Finds Older Medical Marijuana Patients Experience Marked Health, Well-Being Improvements

A recent study has revealed that medical cannabis can offer numerous therapeutic benefits for older adults, positively impacting their mood, sleep, health and well-being. The study observed significant reductions in both pain interference and severity in older adults who use cannabis to manage chronic pain.

Published in the “Drugs and Aging Journal,” the study addresses the limited high-quality studies on marijuana use among older adults. Typically, clinical trials exclude participants older than 65 years of age, even as this demographic increasingly turns to medical cannabis for relief.

The research, which was carried out by a group from Drug Science and the Center for Neuropsychopharmacology at Imperial College London, examined information from the T21 project, a sizable cannabis observational study that was started in the United Kingdom (UK) in 2020.

Since 2018, marijuana-based medical products (CBMPs) have been legally prescribed in the UK. However, access through the National Health Service is limited, with most prescriptions coming from the private market.

The study measured patient outcomes through self-reported overall health, quality of life, sleep and mood metrics. Findings showed steady improvements in all these areas from the start of treatment to a three-month follow-up. Older adults who continued using CBMPs reported significant enhancements in their well-being and overall health.

Further, the study noted that while older patients’ improvements in mood and quality of life were not as significant as those of younger patients (those below 65 years), the advantages were still significant. Improvements in general health and sleep were similar across all age groups.

The researchers emphasized the importance of their findings in filling a gap in the current understanding of medical marijuana use among older adults. They highlighted a nationwide study by the Center for Medical Marijuana that failed to differentiate older persons over age 55, and the UK’s National Statistics Office, which does not gather particular information on marijuana usage by adults over the age of 59. Additionally, they noted that most data does not distinguish between recreational and medical use.

The study also identified distinctions between older and younger patients. Older patients were more likely to be female, report chronic pain as their major condition and be on multiple prescribed medications. They were also less likely to have used cannabis before and to use it daily before starting treatment. When prescribed, older patients were more likely to receive CBD-infused oils and less likely to receive cannabis flower with high-THC potency.

The study concludes that the improvements, even if slightly lower in quality of life and mood for older adults, are significant and add to the limited knowledge about medical marijuana in this age group.

As more becomes known about the specific ways in which different groups of patients, such as seniors, can benefit from medical marijuana products, businesses such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) could see their clientele growing faster in the years to come.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Florida Medical Cannabis Patients Surprised by Email Blast

Florida boasts more than 700,000 medical cannabis patients, and GOP Governor Ron DeSantis, who is currently opposing a proposal to legalize recreational cannabis, wants to highlight his achievements to this targeted group. Recently, Florida’s Health Department sent out an email to medical-cannabis patients, praising DeSantis for signing the state’s budget. The email also promoted a cancer research initiative by First Lady Casey DeSantis and highlighted various health issues addressed in the budget, including syphilis, HIV and hepatitis.

However, the email did not mention medical cannabis, which has raised concerns among advocates and patients who argue that the administration misused the patient list to push political messaging, violating the privacy of these patients. State Representative Kelly Skidmore, the top Democrat on the House Health Policy Committee, criticized the move as a misuse of power and information. She emphasized that patients did not consent to receive promotional material about the governor’s achievements.

In defense of its conduct, the Health Department said that the email was sent to every person in its databases — more than two million people — including the media, the general public, healthcare professionals and licensees. Weesam Khoury, a department spokesperson, did not elaborate on whether comparable marketing made use of patient records for COVID-19, HIV, cancer or other conditions. She was disappointed, she said, that the Associated Press chose to accentuate the annoyance caused by the email over the budget’s noteworthy initiatives.

Advocates argue that the issue extends beyond inconvenience to a breach of privacy. They worry that the broad public-records laws in Florida could allow someone to identify medical-cannabis patients from the email list, because these patients comprise about 35% of the email recipients. This could lead to unwarranted marketing, political messages or even job-related repercussions for patients.

Former agriculture commissioner and state Democratic Party chair Nikki Fried expressed surprise that the state was using the patient email list to promote policies. She said she would have encountered fierce criticism if she had taken similar action with the database of concealed weapons licenses. Fried referred to the action as reckless.

A medical-cannabis patient in Pensacola, who wished to remain anonymous for privacy reasons, mentioned plans to file a formal complaint. The patient compared the situation to a doctor disclosing private patient information for personal gain, insisting that accountability is necessary.

John Morgan, a personal injury attorney who led Florida’s 2016 medical cannabis initiative, questioned whether the email violated federal laws protecting medical information. He suggested that the email list could be highly valuable for political purposes, especially for promoting recreational cannabis legalization in the upcoming November election.

Leading cannabis companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) could be concerned at the casual way in which the health department in Florida is regarding the registry of medical-marijuana patients, given the potentially serious consequences that can result when that data reaches the wrong hands and the loss is traced to a state government agency.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Ohio Companies Prepare for Recreational Cannabis Sales Launch

Ohio’s move from solely medical cannabis sales to also allowing recreational sales is taking a unique path compared to other states. The specific date for the start of recreational sales remains unclear, even though the application period for converting medical cannabis licenses to dual-use began on June 7, 2024. Industry insiders anticipate that the first dual-use licenses might be approved in the coming weeks, but state officials have not confirmed this timeline.

Ohio’s regulators are also prioritizing applications from testing labs, cultivators and processors over retailers. This means cannabis businesses and consumers will see approvals happen in stages based on when applications are submitted and whether applicants meet all necessary criteria, such as inspections and POS systems that differentiate between recreational and medical sales.

Projections suggest that Ohio’s marijuana sales could surpass $1 billion by 2025 and potentially reach $2 billion by 2028. The state’s sizable population (nearly 12 million people) and strategic location are key factors in this growth, likely drawing in many new consumers despite a decline in medical cannabis patients.

Of the five states Ohio borders, only Michigan has licensed recreational cannabis sales. Other states, including Wisconsin and Indiana, still don’t have any form of regulated cannabis program, which could also boost Ohio’s market. Minnesota, meanwhile, is preparing to launch its recreational cannabis market next year.

The move to recreational sales in Ohio was spurred by a voter-approved ballot initiative in a November 2023 special election. When Ohio issues its first recreational licenses, it will become the 21st state in the United States to do so, following Maryland and Missouri, which began their recreational markets in July and February of 2023, respectively. The gap between these launches is the longest seen since the first states legalized recreational cannabis more than 10 years ago.

As the state prepares for the new market, its medical-cannabis sector has seen a decline in sales and patient numbers. The latest figures show 165,746 registered patients, a drop of nearly 15,000 since last November. For comparison, Pennsylvania, with a similar population size, had more than 441,000 registered patients as of April, a figure that has increased by more t han 6,000 since November.

One reason for the decline in Ohio’s medical-cannabis patients could be the lower prices in Michigan, where many Ohio residents purchase their products. In 2023, Ohio’s medical-cannabis dispensaries reported sales of $484 million, a modest 1% increase from the previous year. To support the market, Ohio regulators reduced the fee for caregiver and patient cards to just one cent in March.

Most operators are expected to apply for dual-use licenses. According to the voter-approved law, the converted licenses must be issued by September 7, 2024. Regulators also need to complete the recreational market guidelines by this date. Until then, the market will adhere to medical cannabis standards, delaying the availability of pre-rolls and the increase of THC potency caps on concentrates. Smoking accessories such as rolling papers and delivery services are also restricted.

The wider marijuana industry, including leading entities such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), have their eyes on Ohio and are rooting for this latest addition to the adult-use markets to launch without major hiccups such as those that have dogged the market in New York State.

NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Golden Triangle Ventures Inc. (GTVH) Announces Full Financial Support to Launch Freight Brokerage Division

Cargo Management Group acquisition includes a full-fledged logistics operation, brokerage business, licenses and all associated assets
Acquisition helps move GTVH toward goal of becoming a highly profitable company with minimal to zero debt and a diverse asset portfolio
Along with acquisition, company receives full financial support from T&K Zarro to fund key components of new venture

In a strategic move that aligns with the company’s vision “to assemble a strong portfolio of successful businesses under one overarching umbrella” (https://cnw.fm/HWyV8), Golden Triangle Ventures (OTC: GTVH) (“GTV”) has announced a full-service freight brokerage business designed to significantly expand its logistics capabilities (https://cnw.fm/rMOmx).

The announcement comes as the company completed its acquisition of Cargo Management Group from T&K Zarro LLC (https://cnw.fm/GDTTC) and received the full financial commitment needed to launch the freight brokerage business. The Cargo Management Group acquisition includes a full-fledged logistics operation, brokerage business, licenses and all associated assets.

“The acquisition of Cargo Management Group is a transformative step for GTV,” said Golden Triangle Ventures CEO Steffan Dalsgaard. “This deal provides a scalable business model that will support both Lavish Entertainment and the development of our future flagship project, Destino Ranch. This business, its income and our recently completed renegotiations on our outstanding note will dramatically impact our balance in a positive manner. Additionally, this helps move GTV toward its goal of becoming a highly profitable company with minimal to zero debt and a diverse asset portfolio.”

Golden Triangle Ventures also noted that, along with the acquisition, the company received full financial support from T&K Zarro to fund key components for the freight brokerage business, including state-of-the-art freight brokerage software and load board subscriptions to streamline all operations and improve service delivery. In addition, Cargo Management Group has noted key steps it is planning in order to ensure a successful launch. These steps include establishing a new location and call center to drive sales and manage operations efficiently; hiring and training skilled freight brokers, dispatchers and customer service representatives; and developing a comprehensive marketing strategy to attract new clients and build strong industry partnerships.

Golden Triangle Ventures noted that its new freight brokerage business will leverage Cargo Management Group’s current infrastructure as well as its extensive industry relationships. The company, which reported nearly $3 million in revenue in 2023, has an impressive portfolio of contracts with industry leaders, including J.B. Hunt, C.H. Robinson, Coyote Logistics and Echo Global Logistics. These established partnerships will enable Cargo Management Group to provide comprehensive logistics solutions, including freight brokerage services, to its diverse clientele.

“I am excited to see Cargo Management Group become an official part of Golden Triangle Ventures,” said Tom Zarro, the owner of Cargo Management Group and GTV’s largest note holder. “This acquisition aligns perfectly with GTV’s strategic vision and offers a recession-proof, scalable and profitable business model. With GTV’s expertise and resources, their team has given me full confidence in their ability to expand this enterprise far beyond my current capabilities. As a major investor in GTVH, I remain fully committed to supporting all their endeavors that enhance shareholder value.”

A multifaceted consulting company, Golden Triangle Ventures operates as a parent business pursuing ventures in the health, entertainment and technology sectors. The company is looking to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Opioids, Alcohol Cause Worse SecondHand Harms Compared to Marijuana Use

A recent nationwide study has revealed that secondhand harm from cannabis use is significantly less common than that from alcohol. The study, which surveyed thousands, found that respondents were almost six times more likely to report secondhand alcohol harm than cannabis harm. The perceived risks associated with opioids and other substances also outweighed those associated with marijuana.

The study analyzed responses from 7,799 participants in the 2020 United States National Alcohol Survey. It showed that more than one-third (34.2%) of respondents had experienced alcohol-related secondhand harm at some point in their lives. In contrast, only 5.5% reported experiencing secondhand harm due to marijuana.

Concerning other substances, 7.6% of respondents claimed to have suffered negative effects from the use of opioids by others, and 8.3% reported negative effects from other nonspecific drugs. In the past year, alcohol remained the leading cause of secondhand harm, with 6.2% of respondents affected. This was followed by other substances (2.2%), opioids (2%) and marijuana (1.8%).

The authors also found that different demographic groups had varying experiences with secondhand harm caused by substance use. There were noticeably more reports of secondhand harm from women, white people, those with a family history of alcoholism, and those who were divorced, separated or bereaved. Among these harms were marriage and family problems, road accidents, physical harm, vandalism and money troubles.

For marijuana, a higher likelihood of secondhand harm was reported among Black respondents. However, the authors suggest that many of these harms may be linked to punitive cannabis policies rather than the substance itself.

Interestingly, the survey found that individuals who consumed alcohol were slightly more likely to report secondhand harm. The authors suggest this may be because heavy drinkers are more often in the company of other heavy drinkers. Conversely, frequent cannabis users reported significantly lower odds of experiencing secondhand harm, which aligns with previous research.

Despite the higher reports of alcohol-related secondhand harm compared to cannabis or other substances, the authors expressed some skepticism about the reliability of the participants’ responses. For example, they speculated that marijuana users might report lower cannabis-related secondhand harm because its use often coincides with opioid and alcohol use, leading respondents to attribute harm more to opioids or alcohol than to marijuana.

The study aims to expand the understanding of substance-related harms by focusing on the impact on the family and friends of drug users, not just the users themselves.

Cannabis legalization supporters state that the findings support existing research. Commenting on the study, NORML’s deputy director Paul Armentano noted in a blog post that the public health impact of cannabis is far less severe than that of alcohol, a reality that most adults now recognize.

As more misconceptions about marijuana are dispelled by scientific studies, the industry is likely to deepen its penetration of different markets and create even more opportunities for ancillary companies such as Innovative Industrial Properties Inc. (NYSE: IIPR) that serve marijuana businesses.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Opponents of Cannabis Rescheduling Slam Process FDA Relied On

Representatives of the prohibitionist organization Smart Approaches to Marijuana (SAM) have expressed their disapproval of the government’s plan to categorize cannabis as a Schedule 3 substance. They criticized the move as politically driven and not based on scientific evidence. The group is now exploring all legal avenues to challenge this change and is rallying its supporters to oppose it.

Kevin Sabet, SAM president and CEO, spoke during an online meeting, expressing strong disapproval of the federal officials behind the rescheduling proposal. He argued that the recommendation seemed outdated and inappropriate for 2024. Sabet emphasized that the process is far from over and that a lot of actions can be taken against the proposed change.

The organization’s executive vice president, Luke Niforatos, encouraged opponents of the reform to contact policymakers and voice their concerns. He suggested that the U.S. Drug Enforcement Agency (DEA) had already indicated ways for advocates to push back against the recommendation.

SAM has been disseminating allegations that DEA officials might be against the proposed adjustment ever since the government unveiled its rescheduling proposal in April. Sabet mentioned hearing that DEA director Anne Milgram had not signed off on the proposal, suggesting internal disagreement. Instead, U.S. attorney general Merrick Garland signed the proposed rule, raising further questions during a congressional hearing, where Milgram declined to comment on the matter.

During the SAM event, Sabet acknowledged that substances with proven medical use shouldn’t be in Schedule 1, the most restrictive category of the CSA. However, he criticized the review process by the U.S. Department of Health and Human Services (HHS), which concluded cannabis has proven medical uses. He argued that the process seemed to approve substances based on popularity rather than scientific merit.

Many of the ramifications of officially classifying marijuana as Schedule 3 are still unknown, according to Sabet. One potential change is that state-licensed cannabis businesses could claim tax deductions, which might lead to the industry’s expansion. He and other panelists warned that this could result in increased marijuana use, more access for teenagers and greater risks on the roads. Sabet also downplayed the idea that rescheduling would significantly ease restrictions on marijuana research.

Looking ahead, SAM hopes the DEA might reject the recommendation or consider moving cannabis to Schedule 2. Sabet referenced international law interpretations that seem to require keeping marijuana in Schedule 1 or 2. In 2016, the DEA denied an earlier petition to reschedule cannabis, citing international treaty obligations.

Sabet expressed doubt that rescheduling would prompt the FDA to interfere with state-licensed marijuana markets. However, Niforatos urged followers to press the federal government to utilize postponement as justification for taking action against legally operating states.

The recommendation to reschedule cannabis was officially proposed last month, initiating a public comment period expected to generate diverse responses. Cannabis reform advocates plan to leverage this opportunity, with some supporting reclassification and others pushing for complete descheduling. SAM and other prohibitionists, meanwhile, are expected to continue opposing the policy change via lobbying and potential litigation.

Marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) may have expected this pushback against the rescheduling of cannabis at the federal level, and they will be following the process as it unfolds now that the authorities have opened a comment period regarding the proposed policy change.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Partners with Leading Colombian Company as Global Cannabis Opportunities Increase

“A myriad of opportunities has emerged for (cannabis) investors, entrepreneurs and enthusiasts worldwide,” reports Newsweek
MedCana’s agreement to begin exporting CBD buds to Switzerland appears to be particularly timely
The company noted that this new collaboration marks a “significant milestone” in the company’s expansion into the European market

Interest in cannabis is growing globally, and savvy companies operating in the cannabis space, such as Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), are working to strengthen their positions. Most recently, MedCana announced a new strategic partnership between one of its subsidiaries and a prominent Colombian company to begin export of its first crop of CBD buds to Switzerland within the next six months (https://cnw.fm/CeJOk).

“Since U.S. states such as Colorado initiated the legalization and regulation of recreational cannabis a decade ago, there has been a simultaneous shift in attitudes toward cannabis prohibition in countries around the world,” a recent Newsweek article reported (https://cnw.fm/NJUG4). “As more countries recognize the potential benefits of cannabis, both medically and recreationally, a myriad of opportunities has emerged for investors, entrepreneurs and enthusiasts worldwide.

“Today, the cannabis market worldwide is projected to reach nearly $61 billion in revenue in 2024 and is expected to reach $103 billion by 2028,” the article continued. “With almost 448.4 million people, the European Union has a potential cannabis market larger than the United States and Canada combined. At present, some form of medicinal cannabis is legal in 23 European countries, including Germany, the Netherlands and Italy, and five nations have decriminalized it. Several other European nations are embracing cannabis legalization to varying degrees, while some countries, such as Portugal and Luxembourg, are exploring or have implemented full recreational legalization.”

With these projections, MedCana’s agreement to begin exporting CBD buds to Switzerland appears to be particularly timely. A holding company focused on the cannabis and agricultural technology sectors, MedCana noted that this new collaboration marks a “significant milestone” in the company’s expansion into the European market and its commitment to delivering high-quality CBD products internationally.

“We are thrilled to partner with such a reputable local company in Colombia,” said MedCana CEO Gabriel Diaz. “This partnership not only strengthens our supply chain but also underscores our dedication to bringing premium CBD products to the global market. Switzerland represents a key market for us, and we are excited about the potential growth this collaboration will bring.”

Although the Colombian partner remains unnamed, the entity is known for its excellence in cultivation and processes, and the collaboration is designed to leverage the strengths of both companies to ensure the successful export of CBD buds that meet the high-quality standards of the Swiss market. This strategic move aligns with MedCana’s strategic goals of expanding its footprint in Europe and promoting sustainable agricultural practices in Colombia.

“This collaboration with MedCana is a testament to our shared vision of producing and delivering the highest-quality CBD products,” said Diego Flores, executive director of the Colombian partner. “We are eager to begin this journey and look forward to a prosperous partnership.”

MedCana is committed to advancing cannabis production and agricultural technology around the world, while also driving innovation and promoting sustainability. As the company moves forward with its strategic growth plans, stakeholders can expect to see enhanced profitability and a stronger global presence.

Software Effective Solutions/MedCana is a holding company focused on developing companies in the agricultural technology and cannabis industries. The company remains dedicated to delivering on its promise of building a solid foundation for future growth of its holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Golden Triangle Ventures Inc. (GTVH), Largest Note Holder Reach Agreement That Will Enhance Shareholder Value

GTVH enters pivotal agreement with largest note holder, T&K Zarro LLC
CEO notes that agreement demonstrates “our commitment to strengthening our capital structure and delivering tangible value to our shareholders”
The agreement is a “testament” to the company’s strategic foresight and dedication to fostering a robust and scalable business model

Golden Triangle Ventures (OTC: GTVH) continues momentum as the company announces strategic steps in its commitment to solidifying its capital structure, expanding its business operations and enhancing shareholder value. Most recently, the company revealed a pivotal agreement with T&K Zarro LLC, GTVH’s largest note holder (https://cnw.fm/3mhs9).

“This agreement marks a transformative moment for Golden Triangle Ventures,” said GTVH president Steffan Dalsgaard. “By aligning our interests with T&K Zarro, we are demonstrating our commitment to strengthening our capital structure and delivering tangible value to our shareholders. We are confident that these measures will elevate GTVH to new heights and strengthen our position in the public markets.”

Calling the transaction a “landmark agreement,” Golden Triangle Ventures noted that T&K Zarro has committed to a structured and disciplined sale of GTVH stock, limiting sales to no more than 10% of the daily trading volume on any given day. In addition, the agreement notes that T&K Zarro has agreed to a six-month moratorium on all interest accruals within its convertible debentures held in Golden Triangle.

“This moratorium period is designed to provide GTVH with the necessary time to optimize its operations and capitalize on growth opportunities,” the company noted in the announcement. “This initiative underscores GTVH’s dedication to continuously enhancing shareholder value as the company scales its operations.”

The agreement is “a testament to Golden Triangle Ventures’ strategic foresight and dedication to fostering a robust and scalable business model,” the company continued. According to the announcement, GTVH is focused on reinforcing shareholders’ investment in the company by expanding operations and optimizing capital structure, ultimately creating significant and sustainable growth.

Tom Zarro, president of T&K Zarro, noted that he is fully committed to the long-term success of Golden Triangle Ventures. “This agreement reflects my confidence in the company’s leadership and its vision for growth,” stated Zarro. “By placing a temporary moratorium on interest and adhering to a disciplined approach to stock sales, we are setting the stage for sustainable growth and enhanced shareholder value. I look forward to supporting GTVH as it embarks on this exciting journey.”

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Florida Medical Cannabis Doctors Concerned About Possible Disruptions Once Recreational Use Legalized

Florida’s initiative to legalize recreational marijuana is causing a significant divide within the state’s medical cannabis sector. Florida’s largest medical cannabis company, Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), is supporting Amendment 3, which seeks to legalize recreational cannabis for adults over age 21.

However, approximately 2,000 doctors certified to prescribe medical marijuana are expressing concerns. They warn that this amendment could disrupt access for the state’s 882,000 medical-cannabis patients.

The influx of recreational users could deplete the marijuana products and specific strains that patients rely on for conditions such as severe pain. The passage of Amendment 3 may also result in a reorganization of regulations, giving the Republican-led legislature, which has always favored stricter rules, more authority.

Dr. Michelle Beasley, a Pensacola-based cannabis doctor, finds herself in a difficult position. Although she supports legalization, she is wary of the “poison pill” language in the medical cannabis legislation. This provision states that the law will expire if voters pass another marijuana-related amendment.

The 2017 medical cannabis law, approved by the legislature following the 2016 voter-approved amendment for medical use, contains a sunset clause that mandates the law’s expiration six months after any new marijuana-related constitutional amendment is adopted. The intention was to create a single regulatory framework. However, it also grants the Republican-controlled legislature greater freedom to regulate the industry, potentially reverting to the restrictive low-THC law of 2014 if no new regulations are passed.

Amendment 3 is up for vote in November and requires 60% of the vote to pass. If enacted, it would enable Florida’s authorized medical-cannabis dispensaries to sell to the general public; the legislature would decide on future recreational licenses.

There’s nothing to worry about, according to the campaign supporting Amendment 3. Medical cannabis providers and patients, they claim, are protected by the amendment. Smart and Safe Florida, the committee that supports the legislation, argues that any sunset would be in violation of the 2016 medical cannabis amendment and that the wording referring to “poison pill” is meaningless. They do admit, however, that the sunset provision is not guaranteed.

One of the main proponents of the 2017 law, Senator Jason Brodeur, said that new regulations would be required. He referred to the financial impact statement for 2023, implying that a straightforward interpretation of the wording would necessitate a fresh start.

Over the years, there have been unsuccessful attempts to remove the sunset clause. The most recent attempt failed last year when a bill to limit the amount of THC in recreational cannabis failed to pass.

Doctors are increasingly concerned as polling shows that Amendment 3 could surpass the 60% voting threshold. A Fox News poll released recently indicates that 66% of voters support legalization.

Not all physicians think the sunset clause will be implemented. DocMJ CEO Aaron Bloom doubts the sunset clause is a threat but worries that dispensaries will shift focus from patients to recreational users. Bloom notes that some clinics have already begun stocking items intended for recreational use. He worries that if the focus changes, dispensary employees might not be properly trained to help patients and might even suggest inappropriate goods.

Beasley and others anticipate a decline in business from patients needing follow-up appointments, which are required by the state to continue using medical cannabis. Further, she notes that some patients might find it cheaper to purchase recreational cannabis, avoiding the approximately $500 in doctor visits and annual state fees associated with the medical program. Ultimately, the decision rests with the legislature and voters.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Two New Books Explore Marijuana’s Medical Powers

For those interested in exploring marijuana’s medical benefits, two recently published books —Josh Leddy’s “Living with Cannabis: A Personal Journey” and Dr. Benjamin Caplan’s “The Doctor-Approved Cannabis Handbook” — provide essential insights. The books offer both professional guidance and firsthand accounts, making them invaluable for anyone curious about cannabis’s therapeutic uses.

The book by Dr. Benjamin Caplan offers a thorough manual on medical marijuana use. Caplan, a board-certified family physician with experience treating more than 250,000 patients, reveals his in-depth understanding of the ways that cannabis can help with a range of ailments, including cancer, sleeplessness, cognitive decline and chronic pain. The book explores the science of cannabis, providing lucid descriptions of its workings, appropriate products and dosages.

Caplan highlights the value of guided cannabis therapy, which gives patients autonomy over their care regimens and enables individualized and efficient treatment. The guidebook, which has been recommended by both patients and industry professionals, is a vital tool for everyone considering using cannabis to enhance their health.

Melissa Etheridge, a cannabis activist and cancer survivor, gave high marks to the book. “As a cannabis supporter and cancer survivor, I am aware of the significant role that marijuana plays. Dr. Caplan’s latest book provides an abundance of knowledge along with a significant amount of empathy and understanding,” she said.

On the other hand, Leddy’s book offers a firsthand account of his experience using marijuana as a pain reliever without surgery. Leddy, an entrepreneur and athlete, tells his tale of using cannabis’ healing properties to overcome serious injuries and mental-health issues. The book provides helpful guidance on pain management without requiring invasive procedures or prescription drugs.

Leddy’s story is both intimate and educational, describing his struggles with severe pain and how marijuana changed his life. He highlights the emotional and physical health advantages of cannabis while offering readers tools and ways to manage their own pain and live better.

Together, these books present a well-rounded view of the medical uses of cannabis. They combine expert medical advice with real-life experiences, making them essential reads for anyone interested in the potential benefits of cannabis for health and wellness. Whether you are exploring cannabis for personal use or professional knowledge, “Living with Cannabis: A Personal Journey” and “The Doctor-Approved Cannabis Handbook” provide a wealth of information to help you understand and navigate the therapeutic use of cannabis effectively.

These publications are likely to increase public awareness about the therapeutic potential of the different medical cannabis products made by the numerous licensed companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), and this could motivate more patients to try these products to ease their symptoms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com